Lung Cancer Screening Market size is projected to reach US$ 4.36 Billion by 2028, according to the report. Cancer these days is one of the most common causes of mortality worldwide. Lung cancer is the second most common type of cancer according to World Health Organization (WHO). The number one objective of lung cancers screening is to discover the presence of lung cancers in its earliest possible phase. This screening is usually encouraged for older people with records of long-term smoking, who are currently asymptomatic for lung cancers. Healthcare providers employ low-dose automated tomography (LDCT) scans or X-rays as screening equipment. There is a growing worldwide cognizance of the significance of early detection, which has led to an expanded demand for lung cancers screening.
According to the Lung Cancer Alliance, generally there is 5-year survival rate for lung cancers a significant decline because the disease progresses from stage 1 (with a survival charge starting from 68% to 92%) to stage 4 (with a survival fee as low as 0% to 10%). Growing number of lung cancers cases worldwide is one of the most essential drivers of the lung cancers screening market.
In Australia, lung cancer is the most dangerous kind of cancer, which accounts for a significant percentage of fatality cases. According to the Cancer Australia 2023, early detection of lung cancer is crucial for increasing survival rates. Furthermore, newly developed screening software tries to identify lung tumors in their earliest level, when therapy is more likely to be successful. In July 2021, the Department of Health and Aged Care and Cancer Australia implemented lung cancer screening campaign in Australia.
Furthermore, the global lung cancer screening market is growing due to numerous elements, along with improved utilization of low-dose computed tomography by healthcare specialists. The growing consciousness of innovative and cost-effective lung cancer screening techniques in developing nations like India and China is contributing to the growth of the market. Prominent Market players are pursuing mergers & acquisitions with healthcare establishments to elevate awareness of lung cancer among the population. For instance, Baptist Health South Florida's Miami Cancer Institute (MCI) and Nuance Communications, Inc. collaborated to set up a lung cancer screening program that conducts imaging tests for the early analysis and effective treatment of the lung cancer disease. The lung cancer screening market was valued at US$ 2.85 billion in 2022.
The diagnostic centers sector accounted for fastest developing market percentage all through forecast year. For older peoples, diagnostic facilities are an ideal alternative considering the fact that they offer individualized treatment and reduce the need for repeated health facility visits. In addition to having more manipulated over scheduling of methods, outpatient surgical procedure centers may be 45%-60% much less steeply-priced than hospitals, which advantages patients, insurance, and taxpayers similarly. As a result, compared to sudden sanatorium activities, very few surgical procedures may additionally want to be postponed or rescheduled.
In June 2022, Royal Philips teamed up with Biodesix, Inc. to include the results of Biodesix’s Nodify Lung blood-based totally lung nodule danger evaluation trying out into Philips Lung Cancer Orchestrator lung cancer affected person management machine.
In August 2022, Intelerad Medical Systems acquired PenRad Technologies, Inc., a software company for boosting breast imaging and lung screening productiveness. The acquisition has elevated Intelerad’s product offerings for mammography and lung analytics, optimizing workflow for radiologists and boosting patient fitness outcomes.
The latest report “Lung Cancer Screening Market, Global Forecast By Cancer Type (Non-Small-cell Lung Cancer Diagnostics and Small-cell Lung Cancer Diagnostics), End-User (Hospitals & Clinics, Diagnostic Centers, Research Institute and Others), Country (United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, Netherlands, Switzerland, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, U.A.E, South Africa and Rest of the World), Companies (llumina, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V., Roche Holding AG & Medtronic Plc)” provides a detailed analysis of Lung Cancer Screening Industry.
2. Small-cell Lung Cancer Diagnostics
2. Diagnostic Centers
3. Research Institute
4. Others
1.2 Canada
1.3 Mexico
2.2 United Kingdom
2.3 France
2.4 Italy
2.5 Spain
2.6 Netherlands
2.7 Switzerland
3.2 Japan
3.3 India
3.4 South Korea
3.5 Australia
4.2 Argentina
5.2 U.A.E
5.3 South Africa
2. Abbott Laboratories
3. Thermo Fisher Scientific, Inc
4. QIAGEN N.V.
5. Roche Holding AG.
6. Medtronic plc
According to the Lung Cancer Alliance, generally there is 5-year survival rate for lung cancers a significant decline because the disease progresses from stage 1 (with a survival charge starting from 68% to 92%) to stage 4 (with a survival fee as low as 0% to 10%). Growing number of lung cancers cases worldwide is one of the most essential drivers of the lung cancers screening market.
Lung cancer screening market is projected to grow at a CAGR of 7.34% from 2022 to 2028
The worldwide lung cancers screening market is experiencing sizeable growth due to the growing populace of people who are smokers & tobacco user and improvements in lung cancers screening technology. According to the FDA (Food and Drug Administration), about 2.55 million students used tobacco product in 2021 and according to Centers for Disease Control and Prevention (CDC), almost thirteen out of each one hundred adults' age 18 and older in the United States had been cigarette smokers in 2020. Additionally, the growing occurrence of lung cancer is a leading contributing component to the increasing demand for lung cancer screening.In Australia, lung cancer is the most dangerous kind of cancer, which accounts for a significant percentage of fatality cases. According to the Cancer Australia 2023, early detection of lung cancer is crucial for increasing survival rates. Furthermore, newly developed screening software tries to identify lung tumors in their earliest level, when therapy is more likely to be successful. In July 2021, the Department of Health and Aged Care and Cancer Australia implemented lung cancer screening campaign in Australia.
Furthermore, the global lung cancer screening market is growing due to numerous elements, along with improved utilization of low-dose computed tomography by healthcare specialists. The growing consciousness of innovative and cost-effective lung cancer screening techniques in developing nations like India and China is contributing to the growth of the market. Prominent Market players are pursuing mergers & acquisitions with healthcare establishments to elevate awareness of lung cancer among the population. For instance, Baptist Health South Florida's Miami Cancer Institute (MCI) and Nuance Communications, Inc. collaborated to set up a lung cancer screening program that conducts imaging tests for the early analysis and effective treatment of the lung cancer disease. The lung cancer screening market was valued at US$ 2.85 billion in 2022.
Non-Small Cell Lung Cancer (NSCLC) accounted for largest revenue share in the lung cancers screening market
By Cancer Type, Lung cancer screening market is segmented into Non-Small-cellular Lung Cancer Diagnostics and Small-cellular Lung Cancer Diagnostics. Non-small cell lung cancer (NSCLC) has emerged as the dominant driver of revenue in the lung cancer screening market. This type of lung cancer, recognized for its relative insensitivity to chemotherapy and radiotherapy, has claimed the largest percentage of monetary resources committed to screening and treatment. Its incidence and difficult nature have propelled it to the forefront of research and funding within the area. The vast sales contribution from NSCLC underscores the urgent need for continued advancements in early detection techniques and progressive therapeutic techniques to fight this formidable disease, ultimately improving affected persons consequences and survival costs.Hospitals & clinics section accounted for largest market in the Lung cancers screening market
By End User, Lung cancers screening market is divided into Hospitals & Clinics, Diagnostic Centers, Research Institute and Others. The hospitals & clinics section accounted for largest Market. Hospitals and clinics, equipped with advance diagnostic tools and medical expertise, are at the leading front conducting screenings, diagnosing capability cases, and initiating timely interventions. This substantial market presence signifies the believe patients and healthcare provider place in these facilities for accurate and comprehensive lung cancer screening services. As the primary interface between patients and medical solutions, hospitals and clinics are instrumental in shaping the trajectory of lung cancers management and improving patient outcomes.The diagnostic centers sector accounted for fastest developing market percentage all through forecast year. For older peoples, diagnostic facilities are an ideal alternative considering the fact that they offer individualized treatment and reduce the need for repeated health facility visits. In addition to having more manipulated over scheduling of methods, outpatient surgical procedure centers may be 45%-60% much less steeply-priced than hospitals, which advantages patients, insurance, and taxpayers similarly. As a result, compared to sudden sanatorium activities, very few surgical procedures may additionally want to be postponed or rescheduled.
China lung cancer market is expected to witness significant growth due to the rise in prevalence of lung cancer and increase in demand for early and accurate diagnosis
By Country, Lung cancers screening market is break up into United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, Netherlands, Switzerland, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, U.A.E, South Africa and Rest of the World. China has emerged as a dominant market in the global lung cancers screening market due to its amplified recognition of the advantages associated with early-stage lung cancer screening. With a large populace, China's huge reach enables a wider variety of screenings, raising huge revenue possibilities. Leveraging superior screening technologies and progressive devices, the nation has fortified its role by presenting accurate diagnostics. This dominance stems from heightened focus campaigns that spotlight the advantages of early-degree screening, fostering a proactive method to healthcare. Government assist and innovative guidelines have catalyzed this growth, nurturing an environment conducive to scientific innovation and infrastructure development. China's ascendancy underscores its pivotal function in reshaping the panorama of lung cancer screening, sponsored via a strong confluence of technology, cognizance, and strategic healthcare initiatives.Key Players
Some important players operating in the lung cancers screening market report are lluminaInc, Abbott Laboratories, Thermo Fisher Scientific Inc, QIAGEN N.V., Roche Holding AG and Medtronic percent.In June 2022, Royal Philips teamed up with Biodesix, Inc. to include the results of Biodesix’s Nodify Lung blood-based totally lung nodule danger evaluation trying out into Philips Lung Cancer Orchestrator lung cancer affected person management machine.
In August 2022, Intelerad Medical Systems acquired PenRad Technologies, Inc., a software company for boosting breast imaging and lung screening productiveness. The acquisition has elevated Intelerad’s product offerings for mammography and lung analytics, optimizing workflow for radiologists and boosting patient fitness outcomes.
The latest report “Lung Cancer Screening Market, Global Forecast By Cancer Type (Non-Small-cell Lung Cancer Diagnostics and Small-cell Lung Cancer Diagnostics), End-User (Hospitals & Clinics, Diagnostic Centers, Research Institute and Others), Country (United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, Netherlands, Switzerland, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, U.A.E, South Africa and Rest of the World), Companies (llumina, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V., Roche Holding AG & Medtronic Plc)” provides a detailed analysis of Lung Cancer Screening Industry.
Cancer Type - Lung Cancer Screening Market has been covered from 2 viewpoints:
1. Non-Small-cell Lung Cancer Diagnostics2. Small-cell Lung Cancer Diagnostics
End-User - Lung Cancer Screening Market has been covered from 4 viewpoints:
1. Hospitals & Clinics2. Diagnostic Centers
3. Research Institute
4. Others
Countries - Lung Cancer Screening Market has been covered from 21 viewpoints:
1 North America
1.1 United States1.2 Canada
1.3 Mexico
2 Europe
2.1 Germany2.2 United Kingdom
2.3 France
2.4 Italy
2.5 Spain
2.6 Netherlands
2.7 Switzerland
3 Asia Pacific
3.1 China3.2 Japan
3.3 India
3.4 South Korea
3.5 Australia
4 South America
4.1 Brazil4.2 Argentina
5 Middle East & Africa
5.1 Saudi Arabia5.2 U.A.E
5.3 South Africa
6 Rest of the World
Company Insights:
- Overviews
- Recent Development
- Revenue
Company Analysis:
1. llumina, Inc.2. Abbott Laboratories
3. Thermo Fisher Scientific, Inc
4. QIAGEN N.V.
5. Roche Holding AG.
6. Medtronic plc
Table of Contents
1. Introduction2. Research & Methodology3. Executive Summary
4. Market Dynamics
5. Global Lung Cancer Screening Market and Volume Analysis
6. Market Share - Global Lung Cancer Screening
7. Cancer Type -Global Lung Cancer Screening Market
8. End User - Global Lung Cancer Screening Market
9. North America - Lung Cancer Statistics
10. Europe - Lung Cancer Statistics
11. Asia - Lung Cancer Statistics
12. Latin America - Lung Cancer Statistics
13. Middle East & Africa - Lung Cancer Statistics
14. Porter’s Five Forces
15. SWOT Analysis
16. Company Analysis
List of Figures
List of Tables
Companies Mentioned
- llumina, Inc.
- Abbott Laboratories
- Thermo Fisher Scientific, Inc
- QIAGEN N.V.
- Roche Holding AG.
- Medtronic plc
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 390 |
| Published | September 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 2.85 Billion |
| Forecasted Market Value ( USD | $ 4.36 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 6 |
